Ironwood Pharmaceuticals (IRWD) Total Debt (2013 - 2026)

Ironwood Pharmaceuticals has disclosed Total Debt across 13 years of filings, most recently posting $584.9 million for Q1 2026.

• Total Debt for Q1 2026 came in at $584.9 million, up 51.91% year-over-year; the trailing twelve-month figure through Mar 2026 was $584.9 million (up 51.91% YoY), and the FY2025 annual result was $584.7 million, up 51.86% from the prior year.
• Total Debt came in at $584.9 million for Q1 2026 at Ironwood Pharmaceuticals, roughly flat from $584.7 million in the prior quarter.
• In the past five years, Total Debt ranged from a high of $599.1 million in Q2 2023 to a low of $120.6 million in Q1 2022.
• The 5-year median for Total Debt is $499.6 million (2023), against an average of $473.2 million.
• Across the five-year window, Total Debt slipped 29.06% in 2024 and jumped 51.91% in 2026, its largest moves.
• Ironwood Pharmaceuticals' Total Debt stood at $120.6 million in 2022, then jumped by 314.29% to $499.6 million in 2023, then fell by 22.93% to $385.0 million in 2024, then soared by 51.86% to $584.7 million in 2025, then advanced by 0.03% to $584.9 million in 2026.
• The last three Total Debt figures came in at $584.9 million (Q1 2026), $584.7 million (Q4 2025), and $584.5 million (Q3 2025), per Business Quant data.